Clinical trial
Anti-COVID19 AKS-452 Phase I/II VaccinaTion Study
NCT04681092 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Anti-COVID19 AKS-452 Phase I/II VaccinaTion Study
- Lead sponsor
- University Medical Center Groningen
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- April 6, 2021
- Completion date
- March 10, 2022
- Enrollment
- 112 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
covid19